Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

Smoking cessation and nicotine de-addiction market size to grow by USD 24,529.75 Million: Rising adoption of online retailing remains key growth driver - Technavio


NEW YORK, Dec. 7, 2022 /PRNewswire/ -- The global smoking cessation and nicotine de-addiction market size is set to grow by USD 24,529.75 million from 2022 to 2027, according to Technavio. The growth momentum of the market will accelerate at a CAGR of 12.59% during the forecast period. This report provides analysis and insights to enable effective decision-making. Download A Sample Report

Smoking cessation and nicotine de-addiction market - Key Driver and Major Challenge

The rising adoption of online retailing is driving the smoking cessation and nicotine de-addiction market growth. The rise in the number of internet users across the world has led to an increase in the average amount of money spent online. This coupled with changing buying patterns of consumers has significantly contributed to the growth of online retailing. To capitalize on this trend, vendors are focusing on increasing their presence online. Also, there has been an increase in the number of online pharmacies and drug stores that offer nicotine patches and other NRT products. All these factors are expected to drive the growth of the global smoking cessation and nicotine de-addiction market during the forecast period.

The health issues associated with smoking cessation products is impeding the smoking cessation and nicotine de-addiction market growth. Long-term use of nicotine products can cause health issues such as hair loss, skin irritation, high blood pressure, irregular heartbeat, nausea, and others. Also, people who regularly consume nicotine products face problems with teeth and jaw because of continuous chewing. Other side effects include skin irritation, itching, dizziness, and headache. Moreover, researchers have found that two primary ingredients found in e-cigarettes are toxic to cells in the human body. Many such health risks associated with the consumption of smoking cessation products are reducing the growth potential in the market.

Technavio has identified key trends, drivers, and challenges, along with competitive analysis to help clients improve their strategies to stay ahead of their competitors. Buy the report to obtain detailed insights about the market.

Major Five Smoking cessation and nicotine de-addiction - Companies

Other key vendors

Get lifetime access to our Technavio Insights! Subscribe to our Basic Plan billed annually at USD 5000

Smoking Cessation and Nicotine De-addiction Market Distribution Channel Outlook (Revenue, USD mn, 2022-2027)

Smoking Cessation and Nicotine De-addiction Market Product Outlook (Revenue, USD mn, 2022-2027)

Smoking Cessation and Nicotine De-addiction Market Geography Outlook (Revenue, USD mn, 2022-2027)

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report

What are the key data covered in this smoking cessation and nicotine de-addiction market report?

Related Reports

Smoking Cessation and Nicotine De-addiction Market Scope

Report Coverage

Details

Page number

167

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 12.59%

Market growth 2023-2027

USD 24529.75 million

Market structure

Fragmented

YoY growth 2022-2023 (%)

12.4

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 32%

Key countries

US, Canada, Germany, UK, China, and India

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Alchem International Pvt. Ltd., Alkalon AS, Alvogen, Axcentria Pharmaceuticals, British American Tobacco Plc, Cambrex Corp., CHEMNOVATIC Sp. z o.o. Sp. k, Cipla Ltd., Dr Reddys Laboratories Ltd., Enorama Pharma AB, Imperial Brands Plc, Japan Tobacco Inc., Johnson and Johnson, Lil Drug Store Products Inc., Perrigo Co. Plc, Pfizer Inc., Philip Morris International, Qnovia, Tvape, and Walgreen Co.

Market dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of contents:

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by Distribution Channel

7 Market Segmentation by Product

8 Customer Landscape

9 Geographic Landscape

10 Drivers, Challenges, and Trends

11 Vendor Landscape

12 Vendor Analysis

13 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio


These press releases may also interest you

at 09:50
Exegenesis Bio, a rapidly growing global genetic medicines company, is pleased to announce the presentation of clinical efficacy and safety data from its EXG001-307 Phase 1/2 clinical trial in Spinal Muscular Atrophy (SMA) Type I at the American...

at 09:47
BioAro, a pioneer in genomic research and technology, is set to officially launch PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time insights into the complexities of the human...

at 09:45
Pleio, Inc. and FountainRx announce their partnership to provide a concierge-level experience to specialty pharmacy patients. The two companies are launching a program to provide patients with human-driven support as they onboard onto their specialty...

at 09:45
JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Moleculin Biotech , a clinical stage pharmaceutical company with a...

at 09:41
Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations (CRO), it has decided to conduct clinical trials for its 'niclosamide-based Dengue antiviral' in...

at 09:35
Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively. CancerVision and...



News published on and distributed by: